The results of the first head-to-head trial of Lilly's dual GLP-1/GIP agonist Zepbound (tirzepatide) and Novo Nordisk's GLP-1 agonist Wegovy (semaglutide) have shown experimentally what has been ...

Zepbound is a GLP-1 agonist containing tirzepatide ... and 3.2% (with diabetes). Starting dose: 2.5 mg weekly, increasing to 5 mg after 4 weeks. Doses may continue to increase to a maximum ...

Zepbound single-dose vials are available in 2.5 mg and 5 mg doses ... There is also an FDA box warning for thyroid C-cell tumors for this medication. The prescribing information states that ...

The Food and Drug Administration approved Ozempic for treating patients with chronic kidney disease on Tuesday, marking the latest authorized use for Novo Nordisk’s popular drug known for ...

With its offering of tirzepatide (branded as Mounjaro and Zepbound), Eli Lilly and Co. (NYSE: LLY) was another key pharma player in this new type of treatment for diabetes and obesity.

Eli Lilly and Co. reported that its FDA-approved weight-loss drug Zepbound (tirzepatide) outperformed Novo Nordisk A/S’s Wegovy (semaglutide) in the phase IIIb Surmount-5 trial.

Today, GLP-1 drugs, including Wegovy, Mounjaro and Zepbound, have become household names and key tools in the fight against obesity: 1 in 8 American adults say they have used a GLP-1 drug ...

Emergency, the biopic featuring Kangana Ranaut in the lead role, has seen a further drop in its daily India box office collections on its first Tuesday. The film made ₹2.5 crore on its opening ...

Emergency Box Office Collection Day 5: Kangana Ranaut's film has made its mark at the Indian Box Office, earning ₹12.47 crore in five days. The political drama, marred by censorship issues and ...

Eli Lilly, which manufactures Mounjaro for diabetes and Zepbound for weight loss, did not respond to USA TODAY's request for comment about the research. This story was updated to add new information.

The weight loss drug semaglutide was a "miracle" for Staci Rice. Her cravings and "food noise" disappeared, and it help her lose 64 pounds in around eight months. But, even in its cheaper forms ...

Meanwhile, Leerink Partners analysts doubled down on their confidence in Zepbound's long-term market share. Novo is already licking its wounds from another setbackits experimental two-drug combo ...